Keywords
COVID-19
Approved vaccines
Vaccine limitations
Future plans
Approved vaccines
Vaccine limitations
Future plans
Abstract
Through an unprecedented research and development process, in early 2021, just one year after the COVID-19 pandemic started devastating the world, there are several vaccines commercially available or in advanced phase of testing, each with its own characteristics and challenges. For the first time in the history of vaccination, a global immunization programme has started at a time of intense pandemic activity characterized by high virus transmission, facilitating selection of variants potentially able to escape the vaccine-induced antibody response. The reality is that one cannot rely on a single vaccine when dealing with a pandemic emergency: the urgent need of billions of doses clashes with the production capacity of the pharmaceutical industry. There is therefore no ideal vaccine, but there are many good vaccines to be used immediately. Today, the international debate about COVID-19 vaccines is the hottest topic in global health whether it relates to technical and scientific issues or to the ethical aspects of access to vaccinations for all. This article aims at reviewing the status of vaccines that are used, or about to be used, in immunization campaigns worldwide.
References
[1] Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, Gittleman JL, Daszak P. Global trends in emerging infectious diseases. Nature 2008;451(7181):990-3. doi: 10.1038/nature06536.
[2] Edson D, Field H, McMichael L, Vidgen M, Goldspink L, Broos A, Melville D, Kristoffersen J, de Jong C, McLaughlin A, Davis R, Kung N, Jordan D, Kirkland P, Smith C. Routes of Hendra Virus Excretion in Naturally-Infected Flying-Foxes: Implications for Viral Transmission and Spillover Risk. PLoS One 2015;10(10):e0140670. doi: 10.1371/journal.pone.0140670.
[3] Redding DW, Moses LM, Cunningham AA, Wood J, Jones KE. Environmental-mechanistic modelling of the impact of global change on human zoonotic 2 disease emergence: A case study of Lassa fever. Methods in Ecology and Evolution 2016;7: 646-655. https://doi.org/10.1111/2041-210X.12549
[4] Biden Vows Enough Vaccine ‘for Every Adult in America’ by End of May. New York Times 2021. Available at:
https://www.nytimes.com/2021/03/02/us/politics/merck-johnson-johnson-vaccine.html
Accessed on: 26/03/2021
[5] World Health Organization. The COVID-19 candidate vaccine landscape and tracker. Available at:
https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
Accessed on: 26/03/2021
[6] Coronavirus Vaccine Tracker. The New York Times. Available at:
https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html.
Accessed on 26/03/2021
[7] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020;383(27):2603-2615. doi: 10.1056/NEJMoa2034577.
[8] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T; COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021;384(5):403-416. doi: 10.1056/NEJMoa2035389.
[9] Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B, Lin BC, Doria-Rose NA, O'Dell S, Schmidt SD, Corbett KS, Swanson PA 2nd, Padilla M, Neuzil KM, Bennett H, Leav B, Makowski M, Albert J, Cross K, Edara VV, Floyd K, Suthar MS, Martinez DR, Baric R, Buchanan W, Luke CJ, Phadke VK, Rostad CA, Ledgerwood JE, Graham BS, Beigel JH; mRNA-1273 Study Group. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med 2020;383(25):2427-2438. doi: 10.1056/NEJMoa2028436.
[10] Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Clutterbuck EA, Collins AM, Cutland CL, Darton TC, Dheda K, Dold C, Duncan CJA, Emary KRW, Ewer KJ, Flaxman A, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Galiza E, Goodman AL, Green CM, Green CA, Greenland M, Hill C, Hill HC, Hirsch I, Izu A, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Libri V, Lillie PJ, Marchevsky NG, Marshall RP, Mendes AVA, Milan EP, Minassian AM, McGregor A, Mujadidi YF, Nana A, Padayachee SD, Phillips DJ, Pittella A, Plested E, Pollock KM, Ramasamy MN, Ritchie AJ, Robinson H, Schwarzbold AV, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, White T, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 2021;397(10277):881-891. doi: 10.1016/S0140-6736(21)00432-3.
[11] . AZD1222 US Phase III primary analysis confirms safety and efficacy. AstraZeneca. Available at: https://www.astrazeneca.com/media-centre/press-releases/2021/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy.html. Accessed on: 30/03/2021
[12] Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G, Belij-Rammerstorfer S, Berry L, Bibi S, Bittaye M, Cathie K, Chappell H, Charlton S, Cicconi P, Clutterbuck EA, Colin-Jones R, Dold C, Emary KRW, Fedosyuk S, Fuskova M, Gbesemete D, Green C, Hallis B, Hou MM, Jenkin D, Joe CCD, Kelly EJ, Kerridge S, Lawrie AM, Lelliott A, Lwin MN, Makinson R, Marchevsky NG, Mujadidi Y, Munro APS, Pacurar M, Plested E, Rand J, Rawlinson T, Rhead S, Robinson H, Ritchie AJ, Ross-Russell AL, Saich S, Singh N, Smith CC, Snape MD, Song R, Tarrant R, Themistocleous Y, Thomas KM, Villafana TL, Warren SC, Watson MEE, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Faust SN, Pollard AJ; Oxford COVID Vaccine Trial Group. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet 2021;396(10267):1979-1993. doi: 10.1016/S0140-6736(20)32466-1.
[13] European Medicines Agency. COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets. Available at:
https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots.
Accessed on: 26/03/2021
[14] European Medicines Agency. EMA recommends COVID-19 Vaccine Janssen for authorisation in the EU. Available at:
https://www.aifa.gov.it/documents/20142/1289823/2021.03.11_EMA_Janssen%27s_COVID-19_vaccine_EN.pdf/e6c2b6d2-1d25-7cf1-de11-92f706003360.
Accessed on: 26/03/2021
[15] Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use - First Single-Shot Vaccine in Fight Against Global Pandemic. Available at:
https://www.jnj.com/johnson-johnson-covid-19-vaccine-authorized-by-u-s-fda-for-emergency-usefirst-single-shot-vaccine-in-fight-against-global-pandemic.
Accessed on: 26/03/2021
[16] Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, Stoop J, Tete S, Van Damme W, Leroux-Roels I, Berghmans PJ, Kimmel M, Van Damme P, de Hoon J, Smith W, Stephenson KE, De Rosa SC, Cohen KW, McElrath MJ, Cormier E, Scheper G, Barouch DH, Hendriks J, Struyf F, Douoguih M, Van Hoof J, Schuitemaker H. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med 2021;NEJMoa2034201. doi: 10.1056/NEJMoa2034201.
[17] Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Egorova DA, Shmarov MM, Nikitenko NA, Gushchin VA, Smolyarchuk EA, Zyryanov SK, Borisevich SV, Naroditsky BS, Gintsburg AL; Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 2021;397(10275):671-681. doi: 10.1016/S0140-6736(21)00234-8.
[18] Novavax Inc. Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial. Available at:
https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3.
Accessed on: 26/03/2021
[19] Novavax Inc. Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico. Avaible at:
https://ir.novavax.com/news-releases/news-release-details/novavax-completes-enrollment-prevent-19-covid-19-vaccine-pivotal.
Accessed on: 26/03/2021
[20] European Medicines Agency. EMA starts rolling review of Novavax’s COVID-19 vaccine (NVX-CoV2373). Available at:
https://www.aifa.gov.it/documents/20142/1289823/2021.02.03_com-EMA_COVID-19_Vaccine_Novavax_EN.pdf/a3457f71-74c0-5f9f-224d-4925789c3c87.
Accessed on: 26/03/2021
[21] Dose Finding Study to Evaluate Safety, Tolerability and Immunogenicity of an Inactiviated Adjuvanted Sars-Cov-2 Virus Vaccine Candidate Against Covid-19 in Healthy Adults. Available at:
https://clinicaltrials.gov/ct2/show/NCT04671017.
Accessed on: 26/03/2021
[22] Valneva in Advanced Discussions with European Commission to Supply up to 60 Million Doses of Inactivated, Adjuvanted COVID-19 Vaccine Candidate. Available at:
https://valneva.com/press-release/valneva-in-advanced-discussions-with-european-commission-to-supply-up-to-60-million-doses-of-inactivated-adjuvanted-covid-19-vaccine-candidate/.
Accessed on: 26/03/2021
[23] Coronavirus: Commission concludes exploratory talks with Novavax to secure a new potential vaccine. Available at:
https://ec.europa.eu/commission/presscorner/detail/en/ip_20_2305.
Accessed on: 26/03/2021
[24] COVID-19 – AlFA autorizza la sperimentazione di fase I del vaccino ReiThera in Italia. Available at:
https://www.aifa.gov.it/-/covid-19-alfa-autorizza-la-sperimentazione-di-fase-i-del-vaccino-reithera-in-italia.
Accessed on: 26/03/2021
[25] Reithera announces its GRAd-COV2 COVID-19 vaccine candidate is well tolerated and induces clear immune responses in healthy subjects aged 18-55 years phase 1 trial to advance into elderly subjects aged 65-85 years. Available at:
https://reithera.com/2021/01/14/reithera-announces-its-grad-cov2-covid-19-vaccine-candidate-is-well-tolerated-and-induces-clear-immune-responses-in-healthy-subjects-aged-18-55-years-phase-1-trial-to-advance-into-elderly-subjects-age/?lang=it.
Accessed on: 26/03/2021
[26] Ministero della Salute. Vaccinazioneanti-SARS-CoV-2/COVID-19. Raccomandazioni ad interim sui gruppi target della vaccinazione anti-SARS-CoV-2/COVID-19. Available at:
https://www.vaccinarsi.org/assets/uploads/files/Piano_vaccinale_12_03_rev1_1.pdf
Accessed on: 26/03/2021
[27] Presidenza del Consiglio dei Ministri & Commissario Straordinario per l’attuazione e il coordinamento delle misure sanitarie di contenimento e contrasto dell’emergenza epidemiologica COVID-19. Piano Vaccinale Anticovid. Available at:
http://www.governo.it/sites/governo.it/files/210313_Piano_Vaccinale_marzo_2021.pdf.
Accessed on: 26/03/2021
[28] Report Vaccini Anti COVID-19. Available at:
https://www.governo.it/it/cscovid19/report-vaccini/.
Accessed on: 26/03/2021
[29] Vaccini in tempo reale. Il Sole 24 Ore. Available at:
https://lab24.ilsole24ore.com/numeri-vaccini-italia-mondo/.
Accessed on: 26/03/2021
[30] Rosen B, Waitzberg R, Israeli A. Israel's rapid rollout of vaccinations for COVID-19. Isr J Health Policy Res 2021;10(1):6. doi: 10.1186/s13584-021-00440-6.
[31] WHO. SARS-CoV-2 Variants. Available at:
https://www.who.int/csr/don/31-december-2020-sars-cov2-variants/en/.
Accessed on: 26/03/2021
[32] Shen X, Tang H, McDanal C, Wagh K, Fischer W, Theiler J, Yoon H, Li D, Haynes BF, Sanders KO, Gnanakaran S, Hengartner N, Pajon R, Smith G, Dubovsky F, Glenn GM, Korber B, Montefiori DC. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines. bioRxiv [Preprint] 2021 ;2021.01.27.428516. doi: 10.1101/2021.01.27.428516. Update in: Cell Host Microbe. 2021.
[33] Garcia-Beltran WF, Lam EC, St Denis K, Nitido AD, Garcia ZH, Hauser BM, Feldman J, Pavlovic MN, Gregory DJ, Poznansky MC, Sigal A, Schmidt AG, Iafrate AJ, Naranbhai V, Balazs AB. Circulating SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. medRxiv [Preprint] 2021;2021.02.14.21251704. doi: 10.1101/2021.02.14.21251704. Update in: Cell 2021.
[34] Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, Padayachee SD, Dheda K, Barnabas SL, Bhorat QE, Briner C, Kwatra G, Ahmed K, Aley P, Bhikha S, Bhiman JN, Bhorat AE, du Plessis J, Esmail A, Groenewald M, Horne E, Hwa SH, Jose A, Lambe T, Laubscher M, Malahleha M, Masenya M, Masilela M, McKenzie S, Molapo K, Moultrie A, Oelofse S, Patel F, Pillay S, Rhead S, Rodel H, Rossouw L, Taoushanis C, Tegally H, Thombrayil A, van Eck S, Wibmer CK, Durham NM, Kelly EJ, Villafana TL, Gilbert S, Pollard AJ, de Oliveira T, Moore PL, Sigal A, Izu A; NGS-SA Group Wits–VIDA COVID Group. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med 2021. doi: 10.1056/NEJMoa2102214.
[35] Pangolin: lineage assignment in an emerging pandemic as an epidemiological tool. Available at:
https://cov-lineages.org/global_report_B.1.1.7.html.
Accessed on: 26/03/2021
[36] Saad-Roy CM, Morris SE, Metcalf CJE, Mina MJ, Baker RE, Farrar J, Holmes EC, Pybus OG, Graham AL, Levin SA, Grenfell BT, Wagner CE. Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes. Science 2021; eabg8663. doi: 10.1126/science.abg8663.
[37] Moore JP. Approaches for Optimal Use of Different COVID-19 Vaccines: Issues of Viral Variants and Vaccine Efficacy. JAMA 2021. doi: 10.1001/jama.2021.3465.
[38] Wu K, Werner AP, Moliva JI, Koch M, Choi A, Stewart-Jones GBE, Bennett H, Boyoglu-Barnum S, Shi W, Graham BS, Carfi A, Corbett KS, Seder RA, Edwards DK. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv [Preprint] 2021;2021.01.25.427948. doi: 10.1101/2021.01.25.427948.
[39] Coronavirus: preparing Europe for the increased threat of variants. Available at:
https://ec.europa.eu/commission/presscorner/detail/en/ip_21_641.
Accessed on: 2
[40] World Health Organization. International Health Regulations (2005). Available at:
https://www.who.int/publications/i/item/9789241580496.
Accessed on: 26/03/2021
[41] World Health Organization. International Health Regulations (2005): State Party self-assessment annual reporting tool. Available at:
https://apps.who.int/iris/handle/10665/272432.
Accessed on: 26/03/2021
[42] World Health Organization. Joint external evaluation tool: International Health Regulations (2005) monitoring and evaluation framework. Available at:
https://www.who.int/ihr/publications/WHO_HSE_GCR_2018_2/en/.
Accessed on: 26/03/2021
[43] Wouters OJ, Shadlen KC, Salcher-Konrad M, Pollard AJ, Larson HJ, Teerawattananon Y, Jit M. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet 2021;397(10278):1023-1034. doi: 10.1016/S0140-6736(21)00306-8.
[44] Gavi. What is COVAX? Available at:
https://www.gavi.org/covax-facility#what.
Accessed on: 26/03/2021
[45] The Lancet. Access to COVID-19 vaccines: looking beyond COVAX. Lancet 2021;397(10278):941. doi: 10.1016/S0140-6736(21)00617-6.
[46] World Health Organization. Call to Action: Vaccine Equity Declaration. Available at: https://www.who.int/campaigns/annual-theme/year-of-health-and-care-workers-2021/vaccine-equity-declaration.
Accessed on: 26/03/2021
[2] Edson D, Field H, McMichael L, Vidgen M, Goldspink L, Broos A, Melville D, Kristoffersen J, de Jong C, McLaughlin A, Davis R, Kung N, Jordan D, Kirkland P, Smith C. Routes of Hendra Virus Excretion in Naturally-Infected Flying-Foxes: Implications for Viral Transmission and Spillover Risk. PLoS One 2015;10(10):e0140670. doi: 10.1371/journal.pone.0140670.
[3] Redding DW, Moses LM, Cunningham AA, Wood J, Jones KE. Environmental-mechanistic modelling of the impact of global change on human zoonotic 2 disease emergence: A case study of Lassa fever. Methods in Ecology and Evolution 2016;7: 646-655. https://doi.org/10.1111/2041-210X.12549
[4] Biden Vows Enough Vaccine ‘for Every Adult in America’ by End of May. New York Times 2021. Available at:
https://www.nytimes.com/2021/03/02/us/politics/merck-johnson-johnson-vaccine.html
Accessed on: 26/03/2021
[5] World Health Organization. The COVID-19 candidate vaccine landscape and tracker. Available at:
https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
Accessed on: 26/03/2021
[6] Coronavirus Vaccine Tracker. The New York Times. Available at:
https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html.
Accessed on 26/03/2021
[7] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020;383(27):2603-2615. doi: 10.1056/NEJMoa2034577.
[8] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T; COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021;384(5):403-416. doi: 10.1056/NEJMoa2035389.
[9] Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B, Lin BC, Doria-Rose NA, O'Dell S, Schmidt SD, Corbett KS, Swanson PA 2nd, Padilla M, Neuzil KM, Bennett H, Leav B, Makowski M, Albert J, Cross K, Edara VV, Floyd K, Suthar MS, Martinez DR, Baric R, Buchanan W, Luke CJ, Phadke VK, Rostad CA, Ledgerwood JE, Graham BS, Beigel JH; mRNA-1273 Study Group. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med 2020;383(25):2427-2438. doi: 10.1056/NEJMoa2028436.
[10] Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Clutterbuck EA, Collins AM, Cutland CL, Darton TC, Dheda K, Dold C, Duncan CJA, Emary KRW, Ewer KJ, Flaxman A, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Galiza E, Goodman AL, Green CM, Green CA, Greenland M, Hill C, Hill HC, Hirsch I, Izu A, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Libri V, Lillie PJ, Marchevsky NG, Marshall RP, Mendes AVA, Milan EP, Minassian AM, McGregor A, Mujadidi YF, Nana A, Padayachee SD, Phillips DJ, Pittella A, Plested E, Pollock KM, Ramasamy MN, Ritchie AJ, Robinson H, Schwarzbold AV, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, White T, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 2021;397(10277):881-891. doi: 10.1016/S0140-6736(21)00432-3.
[11] . AZD1222 US Phase III primary analysis confirms safety and efficacy. AstraZeneca. Available at: https://www.astrazeneca.com/media-centre/press-releases/2021/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy.html. Accessed on: 30/03/2021
[12] Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G, Belij-Rammerstorfer S, Berry L, Bibi S, Bittaye M, Cathie K, Chappell H, Charlton S, Cicconi P, Clutterbuck EA, Colin-Jones R, Dold C, Emary KRW, Fedosyuk S, Fuskova M, Gbesemete D, Green C, Hallis B, Hou MM, Jenkin D, Joe CCD, Kelly EJ, Kerridge S, Lawrie AM, Lelliott A, Lwin MN, Makinson R, Marchevsky NG, Mujadidi Y, Munro APS, Pacurar M, Plested E, Rand J, Rawlinson T, Rhead S, Robinson H, Ritchie AJ, Ross-Russell AL, Saich S, Singh N, Smith CC, Snape MD, Song R, Tarrant R, Themistocleous Y, Thomas KM, Villafana TL, Warren SC, Watson MEE, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Faust SN, Pollard AJ; Oxford COVID Vaccine Trial Group. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet 2021;396(10267):1979-1993. doi: 10.1016/S0140-6736(20)32466-1.
[13] European Medicines Agency. COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets. Available at:
https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots.
Accessed on: 26/03/2021
[14] European Medicines Agency. EMA recommends COVID-19 Vaccine Janssen for authorisation in the EU. Available at:
https://www.aifa.gov.it/documents/20142/1289823/2021.03.11_EMA_Janssen%27s_COVID-19_vaccine_EN.pdf/e6c2b6d2-1d25-7cf1-de11-92f706003360.
Accessed on: 26/03/2021
[15] Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use - First Single-Shot Vaccine in Fight Against Global Pandemic. Available at:
https://www.jnj.com/johnson-johnson-covid-19-vaccine-authorized-by-u-s-fda-for-emergency-usefirst-single-shot-vaccine-in-fight-against-global-pandemic.
Accessed on: 26/03/2021
[16] Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, Stoop J, Tete S, Van Damme W, Leroux-Roels I, Berghmans PJ, Kimmel M, Van Damme P, de Hoon J, Smith W, Stephenson KE, De Rosa SC, Cohen KW, McElrath MJ, Cormier E, Scheper G, Barouch DH, Hendriks J, Struyf F, Douoguih M, Van Hoof J, Schuitemaker H. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med 2021;NEJMoa2034201. doi: 10.1056/NEJMoa2034201.
[17] Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Egorova DA, Shmarov MM, Nikitenko NA, Gushchin VA, Smolyarchuk EA, Zyryanov SK, Borisevich SV, Naroditsky BS, Gintsburg AL; Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 2021;397(10275):671-681. doi: 10.1016/S0140-6736(21)00234-8.
[18] Novavax Inc. Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial. Available at:
https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3.
Accessed on: 26/03/2021
[19] Novavax Inc. Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico. Avaible at:
https://ir.novavax.com/news-releases/news-release-details/novavax-completes-enrollment-prevent-19-covid-19-vaccine-pivotal.
Accessed on: 26/03/2021
[20] European Medicines Agency. EMA starts rolling review of Novavax’s COVID-19 vaccine (NVX-CoV2373). Available at:
https://www.aifa.gov.it/documents/20142/1289823/2021.02.03_com-EMA_COVID-19_Vaccine_Novavax_EN.pdf/a3457f71-74c0-5f9f-224d-4925789c3c87.
Accessed on: 26/03/2021
[21] Dose Finding Study to Evaluate Safety, Tolerability and Immunogenicity of an Inactiviated Adjuvanted Sars-Cov-2 Virus Vaccine Candidate Against Covid-19 in Healthy Adults. Available at:
https://clinicaltrials.gov/ct2/show/NCT04671017.
Accessed on: 26/03/2021
[22] Valneva in Advanced Discussions with European Commission to Supply up to 60 Million Doses of Inactivated, Adjuvanted COVID-19 Vaccine Candidate. Available at:
https://valneva.com/press-release/valneva-in-advanced-discussions-with-european-commission-to-supply-up-to-60-million-doses-of-inactivated-adjuvanted-covid-19-vaccine-candidate/.
Accessed on: 26/03/2021
[23] Coronavirus: Commission concludes exploratory talks with Novavax to secure a new potential vaccine. Available at:
https://ec.europa.eu/commission/presscorner/detail/en/ip_20_2305.
Accessed on: 26/03/2021
[24] COVID-19 – AlFA autorizza la sperimentazione di fase I del vaccino ReiThera in Italia. Available at:
https://www.aifa.gov.it/-/covid-19-alfa-autorizza-la-sperimentazione-di-fase-i-del-vaccino-reithera-in-italia.
Accessed on: 26/03/2021
[25] Reithera announces its GRAd-COV2 COVID-19 vaccine candidate is well tolerated and induces clear immune responses in healthy subjects aged 18-55 years phase 1 trial to advance into elderly subjects aged 65-85 years. Available at:
https://reithera.com/2021/01/14/reithera-announces-its-grad-cov2-covid-19-vaccine-candidate-is-well-tolerated-and-induces-clear-immune-responses-in-healthy-subjects-aged-18-55-years-phase-1-trial-to-advance-into-elderly-subjects-age/?lang=it.
Accessed on: 26/03/2021
[26] Ministero della Salute. Vaccinazioneanti-SARS-CoV-2/COVID-19. Raccomandazioni ad interim sui gruppi target della vaccinazione anti-SARS-CoV-2/COVID-19. Available at:
https://www.vaccinarsi.org/assets/uploads/files/Piano_vaccinale_12_03_rev1_1.pdf
Accessed on: 26/03/2021
[27] Presidenza del Consiglio dei Ministri & Commissario Straordinario per l’attuazione e il coordinamento delle misure sanitarie di contenimento e contrasto dell’emergenza epidemiologica COVID-19. Piano Vaccinale Anticovid. Available at:
http://www.governo.it/sites/governo.it/files/210313_Piano_Vaccinale_marzo_2021.pdf.
Accessed on: 26/03/2021
[28] Report Vaccini Anti COVID-19. Available at:
https://www.governo.it/it/cscovid19/report-vaccini/.
Accessed on: 26/03/2021
[29] Vaccini in tempo reale. Il Sole 24 Ore. Available at:
https://lab24.ilsole24ore.com/numeri-vaccini-italia-mondo/.
Accessed on: 26/03/2021
[30] Rosen B, Waitzberg R, Israeli A. Israel's rapid rollout of vaccinations for COVID-19. Isr J Health Policy Res 2021;10(1):6. doi: 10.1186/s13584-021-00440-6.
[31] WHO. SARS-CoV-2 Variants. Available at:
https://www.who.int/csr/don/31-december-2020-sars-cov2-variants/en/.
Accessed on: 26/03/2021
[32] Shen X, Tang H, McDanal C, Wagh K, Fischer W, Theiler J, Yoon H, Li D, Haynes BF, Sanders KO, Gnanakaran S, Hengartner N, Pajon R, Smith G, Dubovsky F, Glenn GM, Korber B, Montefiori DC. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines. bioRxiv [Preprint] 2021 ;2021.01.27.428516. doi: 10.1101/2021.01.27.428516. Update in: Cell Host Microbe. 2021.
[33] Garcia-Beltran WF, Lam EC, St Denis K, Nitido AD, Garcia ZH, Hauser BM, Feldman J, Pavlovic MN, Gregory DJ, Poznansky MC, Sigal A, Schmidt AG, Iafrate AJ, Naranbhai V, Balazs AB. Circulating SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. medRxiv [Preprint] 2021;2021.02.14.21251704. doi: 10.1101/2021.02.14.21251704. Update in: Cell 2021.
[34] Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, Padayachee SD, Dheda K, Barnabas SL, Bhorat QE, Briner C, Kwatra G, Ahmed K, Aley P, Bhikha S, Bhiman JN, Bhorat AE, du Plessis J, Esmail A, Groenewald M, Horne E, Hwa SH, Jose A, Lambe T, Laubscher M, Malahleha M, Masenya M, Masilela M, McKenzie S, Molapo K, Moultrie A, Oelofse S, Patel F, Pillay S, Rhead S, Rodel H, Rossouw L, Taoushanis C, Tegally H, Thombrayil A, van Eck S, Wibmer CK, Durham NM, Kelly EJ, Villafana TL, Gilbert S, Pollard AJ, de Oliveira T, Moore PL, Sigal A, Izu A; NGS-SA Group Wits–VIDA COVID Group. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med 2021. doi: 10.1056/NEJMoa2102214.
[35] Pangolin: lineage assignment in an emerging pandemic as an epidemiological tool. Available at:
https://cov-lineages.org/global_report_B.1.1.7.html.
Accessed on: 26/03/2021
[36] Saad-Roy CM, Morris SE, Metcalf CJE, Mina MJ, Baker RE, Farrar J, Holmes EC, Pybus OG, Graham AL, Levin SA, Grenfell BT, Wagner CE. Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes. Science 2021; eabg8663. doi: 10.1126/science.abg8663.
[37] Moore JP. Approaches for Optimal Use of Different COVID-19 Vaccines: Issues of Viral Variants and Vaccine Efficacy. JAMA 2021. doi: 10.1001/jama.2021.3465.
[38] Wu K, Werner AP, Moliva JI, Koch M, Choi A, Stewart-Jones GBE, Bennett H, Boyoglu-Barnum S, Shi W, Graham BS, Carfi A, Corbett KS, Seder RA, Edwards DK. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv [Preprint] 2021;2021.01.25.427948. doi: 10.1101/2021.01.25.427948.
[39] Coronavirus: preparing Europe for the increased threat of variants. Available at:
https://ec.europa.eu/commission/presscorner/detail/en/ip_21_641.
Accessed on: 2
[40] World Health Organization. International Health Regulations (2005). Available at:
https://www.who.int/publications/i/item/9789241580496.
Accessed on: 26/03/2021
[41] World Health Organization. International Health Regulations (2005): State Party self-assessment annual reporting tool. Available at:
https://apps.who.int/iris/handle/10665/272432.
Accessed on: 26/03/2021
[42] World Health Organization. Joint external evaluation tool: International Health Regulations (2005) monitoring and evaluation framework. Available at:
https://www.who.int/ihr/publications/WHO_HSE_GCR_2018_2/en/.
Accessed on: 26/03/2021
[43] Wouters OJ, Shadlen KC, Salcher-Konrad M, Pollard AJ, Larson HJ, Teerawattananon Y, Jit M. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet 2021;397(10278):1023-1034. doi: 10.1016/S0140-6736(21)00306-8.
[44] Gavi. What is COVAX? Available at:
https://www.gavi.org/covax-facility#what.
Accessed on: 26/03/2021
[45] The Lancet. Access to COVID-19 vaccines: looking beyond COVAX. Lancet 2021;397(10278):941. doi: 10.1016/S0140-6736(21)00617-6.
[46] World Health Organization. Call to Action: Vaccine Equity Declaration. Available at: https://www.who.int/campaigns/annual-theme/year-of-health-and-care-workers-2021/vaccine-equity-declaration.
Accessed on: 26/03/2021